GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyclo Therapeutics Inc (NAS:CYTH) » Definitions » Cyclically Adjusted Revenue per Share

CYTH (Cyclo Therapeutics) Cyclically Adjusted Revenue per Share : $1.26 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Cyclo Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Cyclo Therapeutics's adjusted revenue per share for the three months ended in Sep. 2024 was $0.008. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.26 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Cyclo Therapeutics's average Cyclically Adjusted Revenue Growth Rate was -22.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -14.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -9.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -7.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Cyclo Therapeutics was -4.40% per year. The lowest was -14.30% per year. And the median was -7.60% per year.

As of today (2025-03-04), Cyclo Therapeutics's current stock price is $0.7125. Cyclo Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was $1.26. Cyclo Therapeutics's Cyclically Adjusted PS Ratio of today is 0.57.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cyclo Therapeutics was 37.91. The lowest was 0.39. And the median was 6.85.


Cyclo Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Cyclo Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclo Therapeutics Cyclically Adjusted Revenue per Share Chart

Cyclo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.61 2.43 2.26 2.06 1.53

Cyclo Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.62 1.53 1.39 1.35 1.26

Competitive Comparison of Cyclo Therapeutics's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Cyclo Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclo Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyclo Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cyclo Therapeutics's Cyclically Adjusted PS Ratio falls into.



Cyclo Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cyclo Therapeutics's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.008/133.0289*133.0289
=0.008

Current CPI (Sep. 2024) = 133.0289.

Cyclo Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 0.820 99.070 1.101
201503 0.317 99.621 0.423
201506 0.697 100.684 0.921
201509 0.410 100.392 0.543
201512 0.276 99.792 0.368
201603 0.533 100.470 0.706
201606 0.632 101.688 0.827
201609 0.416 101.861 0.543
201612 0.787 101.863 1.028
201703 0.440 102.862 0.569
201706 0.717 103.349 0.923
201709 0.330 104.136 0.422
201712 0.230 104.011 0.294
201803 0.271 105.290 0.342
201806 0.442 106.317 0.553
201809 0.257 106.507 0.321
201812 0.273 105.998 0.343
201903 0.243 107.251 0.301
201906 0.270 108.070 0.332
201909 0.236 108.329 0.290
201912 0.187 108.420 0.229
202003 0.268 108.902 0.327
202006 0.148 108.767 0.181
202009 0.131 109.815 0.159
202012 0.031 109.897 0.038
202103 0.067 111.754 0.080
202106 0.038 114.631 0.044
202109 0.063 115.734 0.072
202112 0.079 117.630 0.089
202203 0.023 121.301 0.025
202206 0.064 125.017 0.068
202209 0.054 125.227 0.057
202212 0.022 125.222 0.023
202303 0.014 127.348 0.015
202306 0.008 128.729 0.008
202309 0.031 129.860 0.032
202312 0.014 129.419 0.014
202403 0.007 131.776 0.007
202406 0.004 132.554 0.004
202409 0.008 133.029 0.008

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Cyclo Therapeutics  (NAS:CYTH) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Cyclo Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.7125/1.26
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cyclo Therapeutics was 37.91. The lowest was 0.39. And the median was 6.85.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Cyclo Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Cyclo Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclo Therapeutics Business Description

Industry
Traded in Other Exchanges
N/A
Address
6714 North West 16th Street, Suite B, Gainesville, FL, USA, 32653
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
Executives
Vivien Wong director 6C CHATEAUX CIRCLE, SCARSDALE NY 10583
Rafael Holdings, Inc. 10 percent owner 520 BROAD STREET, NEWARK NJ 07120
William Conkling director C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Jeffrey Tate director, officer: Chief Executive Officer C/O CTD HOLDINGS, INC., 27317 NW 78TH AVENUE, HIGH SPRINGS FL 32643
Francis Patrick Ostronic director 932 HUNGERFORD DRIVE, SUITE 28A, ROCKVILLE MD 20850
Markus Sieger director BEUTSTWEG 12, CH-8032, ZURICH V8 000000000
N Scott Fine director 600 3RD AVE, NEW YORK NY 10016
Sharon Hemond Hrynkow officer: SVP for Medical Affairs 4816 KING SOLOMON DRIVE, ANNADALE VA 22003
Lise Lund Kjems officer: Chief Medical Officer 91 ROLLINGWOOD LN., CONCORD MA 01742
Joshua M Fine officer: Chief Financial Officer 21 HEMMELSKAMP ROAD, WILTON CT 06897
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Michael Eric Lisjak officer: Chief Regulatory Officer 12 ROOSEVELT AVENUE, OLD GREENWICH CT 06870
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
L.p. Novit, 10 percent owner 966 HUNGERFORD DRIVE, ROCKVILLE MD 20850